Glimepiride

Glimepiride is a third generation sulfonylurea compound, which increases the release of insulin from pancreatic beta cells. In addition, glimepiride increases the activity of intracellular insulin receptors. Glimepiride increases osteoblast proliferation and differentiation, which is thought to be related to its ability to activate the PI3K and Akt pathway. Furthermore, Glimepiride enhances intrinsic peroxisome proliferator-activated receptor γ activity. Glimepiride also increases protein expression of glucose transports 1 and 4, and is a potent KIR channel blocker.

Properties:

Appearance & Physical State: White Cyrstalline Solid
Density: 1.29 g/cm3
Melting Point: 212-214ºC
Refractive Index: 1.599

Potassium Channel Inhibitors Related Prodcuts:

Vonoprazan Fumarate; Gliclazide; Almitrine dimesylate; JNJ303; Dofetilide; Dronedarone HCl; Mitiglinide Calcium; Glyburide; ML213

[1]. Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38(8): p. 1120-30.

[2]. Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4.